健脾补肾方联合西药治疗特发性矮小症脾肾两虚证临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R272

基金项目:


Clinical Study on Jianpi Bushen Prescription Combined with Western Medicine for Idiopathic Short Stature with Spleen and Kidney Deficiency Syndrome
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察健脾补肾方联合西药治疗特发性矮小症(ISS) 脾肾两虚证的临床疗效及对生长激素释 放激素(GHRH) /生长激素(GH) /胰岛素样生长因子-1(IGF-1) 轴的影响。方法:选取2023年1—12月在 兰溪市人民医院儿科治疗的98例ISS脾肾两虚证患儿,按简单随机法分为常规组和综合组各49例。常规组给 予重组人生长激素加赖氨肌醇维B12治疗,综合组在常规组基础上联合健脾补肾方治疗,连续治疗6个月。比较 2组身高、体质量、骨龄、预测身高、中医证候评分及克洛索蛋白(Klotho)、骨碱性磷酸酶(BAP)、GH、 IGF-1、胰岛素样生长因子结合蛋白3(IGFBP-3)、GHRH。记录2组不良反应。结果:治疗后,2组身高、体 质量、骨龄及预测身高均较治疗前升高(P<0.05),综合组身高、体质量、预测身高均高于常规组(P< 0.05)。2组中医证候评分均较治疗前降低(P<0.05),综合组中医证候评分均低于常规组(P<0.05)。2组 Klotho、BAP、GH、IGF-1、IGFBP-3、GHRH均较治疗前升高(P<0.05),综合组Klotho、BAP、GH、IGF-1、 IGFBP-3、GHRH均高于常规组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论: 健脾补肾方联合西药治疗ISS脾肾两虚证可改善生长激素的分泌以及骨代谢,促进患儿生长发育,安全性好。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Jianpi Bushen Prescription combined with western medicine in treating idiopathic short stature (ISS) with spleen and kidney deficiency syndrome and its effects on the growth hormone-releasing hormone (GHRH)/growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis. Methods: A total of 98 cases of children with ISS with spleen and kidney deficiency syndrome treated in the Department of Chinese Medicine Pediatrics at Lanxi People's Hospital from January to December 2023,were selected and randomly divided into the conventional group and the comprehensive group using the simple random method,with 49 cases in each group. The conventional group was treated with Recombinant Human Growth Hormone combined with Lysine Inositol and Vitamin B12,and the comprehensive group was additionally treated with Jianpi Bushen Prescription based on the treatment of the conventional group. Both groups were treated continuously for six months. The height, weight, bone age, predicted height, traditional Chinese medicine (TCM) syndrome scores, and levels of Klotho protein,bone alkaline phosphatase (BAP),GH,IGF-1,insulin-like growth factor-binding protein 3 (IGFBP-3), and GHRH in the two groups were compared before and after treatment. Adverse reactions in both groups were recorded. Results:After treatment,the height,weight,bone age,and predicted height in the two groups were increased when compared with those before treatment (P<0.05), with the comprehensive group showing greater improvements in height,weight,and predicted height than the conventional group (P<0.05). TCM syndrome scores in the two groups were decreased when compared with those before treatment (P<0.05), with the comprehensive group showing lower scores than the conventional group (P<0.05). The levels of Klotho protein, BAP, GH, IGF-1, IGFBP-3, and GHRH in the two groups were increased when compared with those before treatment (P<0.05), with the comprehensive group showing higher levels than the conventional group (P<0.05). There was no significant difference being found in the comparison of the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Jianpi Bushen Prescription combined with western medicine for ISS with spleen and kidney deficiency syndrome can improve the secretion of GH and bone metabolism and promote the growth and development of children,with good safety.

    参考文献
    相似文献
    引证文献
引用本文

方翔.健脾补肾方联合西药治疗特发性矮小症脾肾两虚证临床研究[J].新中医,2025,57(11):100-104

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-06-13
  • 出版日期:
文章二维码